Nordson is a premium niche industrial compounder with a 50% recurring revenue base, strong Q3 execution, and a probability-weighted five-year target of $418.39 versus $308.72 today.
Overview
Nordson is a decentralized, division-led industrial technology company serving high-barrier manufacturing and medical niches through Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions. Its equipment is integrated into customers’ high-speed processes, making reliability, yield, and technical support more important than initial price. Approximately 50% of sales are recurring aftermarket parts, consumables, and maintenance, while 67% of revenue is international. Q3 fiscal 2026 was a record quarter: sales rose 10% year over year to **$818 million**, adjusted EPS increased 19% to **$3.25**, and EBITDA reached $262 million at a 32% margin. ATS led with 28% sales growth, while backlog increased 35%. Management raised FY2026 revenue guidance to $3,035–$3,075 million and adjusted EPS to $11.80–$12.00. Valuation is premium at 33.1x trailing P/E and 20.1x EV/EBITDA, but reflects moat, recurring revenue, medical exposure, and cash conversion. Shares were $308.72 in the scenario framework, with analyst targets of $335–$345 and a five-year probability-weighted target of $418.39. Near-term catalysts are continued ATS demand, medical integration, backlog conversion, and further estimate revisions.